<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6562">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03021499</url>
  </required_header>
  <id_info>
    <org_study_id>AUR-VCS-2016-01</org_study_id>
    <nct_id>NCT03021499</nct_id>
  </id_info>
  <brief_title>Aurinia Renal Response in Active Lupus With Orelvo (Voclosporin)</brief_title>
  <acronym>AURORA</acronym>
  <official_title>A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (Voclosporin) (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Orelvo (voclosporin) compared with
      placebo in achieving renal response after 24 weeks of therapy in subjects with active lupus
      nephritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the current study is to investigate whether Orelvo, added to the standard of care
      treatment in active lupus nephritis (LN), is able to reduce disease activity over a
      treatment period of 24 weeks. The background therapy will be MMF and initial treatment with
      IV methylprednisolone, followed by a reducing course of oral corticosteroids. Subjects with
      active, flaring LN will be eligible to enter the study. They are required to have a
      diagnosis of LN according to established diagnostic criteria and clinical and biopsy
      features suggestive of active nephritis. Efficacy will be assessed by the ability of the
      drug combination to reduce the level of proteinuria (as measured by urine protein/creatinine
      ratio (UPCR) while demonstrating an acceptable safety profile.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects achieving renal response</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The number of subjects achieving renal response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to UPCR of ≤0.7 mg/mg.</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Time to UPCR of ≤0.7 mg/mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial renal response</measure>
    <time_frame>Weeks 24 and 52</time_frame>
    <description>Partial renal response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% reduction in UPCR from baseline.</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Time to 50% reduction in UPCR from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal response at Week 52</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Renal response at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of renal response</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Duration of renal response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory parameters at each time point</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Change from baseline in laboratory parameters at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal response with low-dose steroids</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Renal response with low-dose steroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaires</measure>
    <time_frame>Weeks 12, 24 and 52</time_frame>
    <description>Quality of Life questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the SELENA-SLEDAI Index score</measure>
    <time_frame>Weeks 24 and 52</time_frame>
    <description>Change from baseline in the SELENA-SLEDAI Index score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Voclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral, 23.7 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Voclosporin placebo, oral, 3 capsules BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voclosporin</intervention_name>
    <description>calcineurin inhibitor</description>
    <arm_group_label>Voclosporin</arm_group_label>
    <other_name>Orelvo</other_name>
    <other_name>ISA247</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>matching placebo capsule</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        - Subjects with evidence of active nephritis, defined as follows:

          -  Kidney biopsy result within 2 years prior to screening indicating Class III, IV-S or
             IV-G (alone or in combination with Class V) LN with a doubling or greater increase of
             UPCR within the last 6 months to a minimum of ≥1.5 mg/mg at screening.

        OR

          -  Kidney biopsy result within 6 months prior to screening indicating Class III, IV-S or
             IV-G (alone or in combination with Class V) LN with a UPCR of ≥1.5 mg/mg at
             screening.

        OR

          -  Kidney biopsy result within 6 months prior to screening indicating Class V LN and a
             UPCR of ≥2 mg/mg at screening.

               -  Women of childbearing potential must have a negative serum pregnancy test at
                  screening and a negative urine pregnancy test at baseline.

        Exclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) of ≤45 mL/minute at screening.

          -  Current or medical history of:

               -  Congenital or acquired immunodeficiency.

               -  In the opinion of the Investigator, clinically significant drug or alcohol abuse
                  within 2 years prior to screening.

               -  Malignancy within 5 years of screening, with the exception of basal and squamous
                  cell carcinomas treated by complete excision.

               -  Lymphoproliferative disease or previous total lymphoid irradiation.

               -  Severe viral infection or known HIV infection.

               -  Active tuberculosis (TB), or known history of TB/evidence of old TB if not
                  taking prophylaxis with isoniazid.

          -  Other known clinically significant active medical conditions, such as:

               -  Severe cardiovascular disease, liver dysfunction or chronic obstructive
                  pulmonary disease or asthma requiring oral steroids or any other overlapping
                  autoimmune condition for which the condition or the treatment of the condition
                  may affect the study assessments or outcomes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Anne Dooley, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Huizinga</last_name>
    <email>rhuizinga@auriniapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rashieda Gluck</last_name>
    <email>rgluck@auriniapharma.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, Hooi LS, Brunetta P, Maciuca R, Solomons N. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013 Jan;8(1):147-53. doi: 10.2215/CJN.03290412. Epub 2012 Aug 9. Review.</citation>
    <PMID>22879439</PMID>
  </reference>
  <reference>
    <citation>Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309.</citation>
    <PMID>24330024</PMID>
  </reference>
  <reference>
    <citation>Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013 Dec;53(12):1303-12. doi: 10.1002/jcph.166. Epub 2013 Oct 8.</citation>
    <PMID>23996158</PMID>
  </reference>
  <reference>
    <citation>Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. J Clin Pharmacol. 2013 Aug;53(8):819-26. doi: 10.1002/jcph.114. Epub 2013 Jun 4.</citation>
    <PMID>23736966</PMID>
  </reference>
  <results_reference>
    <citation>Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group.. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460.</citation>
    <PMID>22087680</PMID>
  </results_reference>
  <results_reference>
    <citation>Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators.. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22.</citation>
    <PMID>21943027</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>January 12, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lupus nephritis</keyword>
  <keyword>calcineurin inhibitors</keyword>
  <keyword>voclosporin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
